Zhongda Hospital

This study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard drug therapy (immunotherapy plus anti-angiogenesis drugs) improves survival in people with advanced liver cancer that has spread into the main blood vessel of the liver. Over 1,600 particip…

This study tested a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), immunotherapy (PD-1/PD-L1 inhibitors), and targeted drugs (VEGF-TKI or bevacizumab)—in over 1,200 people with advanced liver cancer that had spread. The goal was to see if …

This study looked at adding a procedure called TACE (which blocks the tumor's blood supply) to a mix of immunotherapy and targeted drugs for people with advanced liver cancer that has spread into major blood vessels. Over 2,600 participants were included. The goal was to see if t…

This study tested a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), immunotherapy (PD-1/PD-L1 inhibitors), and targeted drugs (VEGF-TKI or bevacizumab)—in 941 people with intermediate-stage liver cancer. The goal was to see if this triple t…

This study tested a combination of three treatments—chemotherapy directly into the liver, a targeted drug, and an immunotherapy—for people with advanced bile duct cancer that cannot be removed by surgery. The goal was to see if the combination is safe and shrinks tumors. 25 parti…